<DOC>
	<DOCNO>NCT02040506</DOCNO>
	<brief_summary>This study examine safety tolerability IGN523 administer IV infusion . The main purpose study determine maximum tolerate dose ( MTD ) , high dose cause unacceptable side effect IGN523 patient acute myeloid leukemia ( AML ) . The MTD determine observe dose-limiting toxicity ( side effect prevent increase dose ) IGN523 . In addition , pharmacokinetic profile anti-leukemia activity IGN523 assess . A recommended Phase 2 dose ( RP2D ) IGN523 identify , basis safety , pharmacokinetic ( PK ) , pharmacodynamic ( PD ) data .</brief_summary>
	<brief_title>A Phase I Study IGN523 Subjects With Relapsed Refractory AML</brief_title>
	<detailed_description>Primary Objectives : - Evaluate safety tolerability IGN523 administer weekly - Determine MTD dose limit toxicity ( DLT ) IGN523 administer weekly DLT Evaluation Period - Identify recommend Phase 2 dose ( RP2D ) IGN523 basis safety , PK , PD data Secondary Objectives : - Assess incidence antibody formation IGN523 - Characterize PK IGN523 subject relapse refractory AML - Perform preliminary assessment anti-leukemic activity IGN523 subject relapse refractory AML - Perform preliminary assessment biologic marker might predict IGN523 anti-leukemic activity Estimated Enrollment : 50 Study Start Date : February 2014 Estimated Study Completion Date : March 2016 Estimated Primary Completion Date : September 2015 ( Final data collection primary outcome measure )</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Relapsed treatmentrefractory AML Eastern Cooperative Oncology Group status 02 Life expectancy least 12 week Adequate baseline renal hepatic function Measurable disease ( eg , peripheral blast great 5 % ) Chronic myelogenous leukemia blast crisis Monoclonal therapy within 4 week , chemotherapy radiotherapy within 2 week Unresolved acute toxicity prior anticancer therapy Prior allogeneic stem cell transplant active graftversushost disease require systemic immunosuppressive therapy within 15 day prior screen History severe allergic anaphylactic reaction monoclonal antibody therapy Known current leptomeningeal central nervous system ( CNS ) involvement leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Drug therapy</keyword>
	<keyword>CD98</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>